Exelixis, Inc.
1851 Harbor Bay Parkway
Alameda
California
94502
United States
Tel: 650-837-7000
Website: http://www.exelixis.com/
680 articles with Exelixis, Inc.
-
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) Tablets for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib
11/15/2018
EC approval triggers $40 million milestone payment to Exelixis under Collaboration Agreement with Ipsen
-
Exelixis to Present at the Stifel 2018 Healthcare Conference on November 13, 2018
11/6/2018
Presentation to be webcast on www.exelixis.com
-
Exelixis Announces Third Quarter 2018 Financial Results and Provides Corporate Update
11/1/2018
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2018 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
-
Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma
10/22/2018
Combination of cabozantinib and atezolizumab is well tolerated and shows promising anti-tumor activity
-
Exelixis Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma
10/20/2018
Exelixis, Inc. (NASDAQ:EXEL) today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC).
-
Exelixis to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018
10/18/2018
Exelixis, Inc. (NASDAQ: EXEL) announced today that its third quarter 2018 financial results will be released on Thursday, November 1, 2018 after the markets close.
-
CLSA Names Pantheon DiNA Award Winners
10/9/2018
Bristol-Myers Squibb, Nektar Therapeutics, Amgen and others will be recognized for their significant contributions to the California life sciences industry during the November 2018 Pantheon DiNA Awards hosted by the California Life Sciences Association. -
Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress
10/8/2018
Presentations to include results from the dose escalation stage of phase 1b COSMIC-021 study of cabozantinib in combination with atezolizumab in previously untreated advanced renal cell carcinoma
-
Exelixis Initiates Phase 3 Pivotal Trial (COSMIC-311) of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
10/8/2018
Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of a phase 3 pivotal trial (COSMIC-311) of single-agent cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies.
-
Exelixis to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018
9/25/2018
Presentation to be webcast on www.exelixis.com
-
Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
9/21/2018
In the phase 3 pivotal CELESTIAL trial, CABOMETYX demonstrated a statistically significant and clinically meaningful overall survival benefit
-
Exelixis to Present at the Morgan Stanley Global Health Care Conference on September 12, 2018
9/5/2018
— Presentation to be webcast on www.exelixis.com —
-
Exelixis Announces Second Quarter 2018 Financial Results and Provides Corporate Update
8/1/2018
Total Revenues of $186.1 million, Net Income of $87.5 million, Diluted EPS of $0.28
-
Exelixis to Release Second Quarter 2018 Financial Results on Wednesday, August 1, 2018
7/17/2018
Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m. PDT
-
Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine
7/4/2018
Trial results formed the basis of regulatory filings in the U.S. and European Union for CABOMETYX® (cabozantinib) for previously treated advanced hepatocellular carcinoma
-
Exelixis to Present at the William Blair & Co. 38th Annual Growth Stock Conference on June 12, 2018
6/5/2018
Exelixis, Inc. announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the William Blair 2018 Growth Stock Conference
-
Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018
6/3/2018
June 3, 2018 13:00 UTC Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018 – Cabozantinib improved overall survival and progression-free survival irrespective of duration of prior sorafenib treatment or age category – SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Exelixis, Inc. (Nasdaq: EXE
-
Exelixis Announces Further Expansion to Clinical Research Protocol for Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Anti-PD-L1 Immunotherapy in Patients with Locally Advanced or Metastatic Solid Tumors
6/1/2018
– Ten new trial cohorts added to expansion phase of combination trial, bringing the total number of cohorts to 18 –
-
Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX® (cabozantinib) in Previously Treated Advanced Hepatocellular Carcinoma
5/29/2018
Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s supplemental New Drug Application (sNDA) for CABOMETYX® (cabozantinib) tablets.
-
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.